It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to reduce costs and shorten the time it ...

The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...

So far, the USFDA has approved 76 biosimilars but the market share of these remains below 20% with only 10% of the biologics ...

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

Sai Life Sciences announces the groundbreaking of a state-of-the-art CMC Process R&D Center in Hyderabad, poised to double ...

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges Thermo Fisher Scientific Inc., the world leader in ...

The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary ...

Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

Researchers at Harvard Medical School developed a tool that uses artificial intelligence to accelerate drug discovery and development. The new technology, called PDGrapher, applies machine learning to ...

The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...